More AIDS Funds Asked

WASHINGTON-The question this summer for AIDS researchers is not whether, but by how much, the federal budget will be increased for work on the disease. President Reagan recently boosted his budget request to $523 million, up from the $413 million originally sought in fiscal 1988 for Public Health Service efforts to fight the disease. The additional money would increase funding for research on the causes of the disease to $266 million, and provide $257 million for the development of treatments an

Written byAmy Mcdonald
| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

President Reagan recently boosted his budget request to $523 million, up from the $413 million originally sought in fiscal 1988 for Public Health Service efforts to fight the disease. The additional money would increase funding for research on the causes of the disease to $266 million, and provide $257 million for the development of treatments and vaccines. The administration has also increased from $120 million to $268 million its proposed spending on education and information programs.

The $1 trillion non-binding federal budget plan approved by the House and Senate late last month assumes $550 million next year for AIDS research. The resolution calls for an additional $420 million for prevention, treatment and drug testing efforts.

The Senate Labor and Human Resources Committee last month unanimously approved a comprehensive AIDS bill that calls for open-ended funding for research. The legislation, introduced by committee Chairman Edward M. Kennedy (D-Mass.), authorizes a minimum ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies